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Mutations in the NAGLU gene cause Sanfilippo B syndrome (mu-
copolysaccharidosis IIIB), a rare lysosomal storage disorder whose main
symptom is a severe and progressive neurodegeneration for which no
treatment is still available. Here, we generated two homozygous
NAGLU-mutated cell lines using CRISPR/Cas9 editing in a healthy
human induced pluripotent stem cell (hiPSC) line. These novel cell lines
express pluripotency specific markers and maintain their capability to
differentiate into all three germ layers in vitro while exhibit a normal
karyotype. These mutated lines in combination with the isogenic con-
trol line will be useful to model in vitro Sanfilippo B syndrome.
Resource Table
Unique stem cell lines
identifier
UBi001-A-3 and UBi001-A-4




Institution University of Barcelona (Barcelona, Spain) and Lund Stem
Cell Center (Lund, Sweden)
Contact information of
distributor
Isaac Canals - isaac.canals@med.lu.se,
Daniel Grinberg - dgrinberg@ub.edu
Type of cell lines Induced pluripotent stem cell line
Origin Human





Retrovirus (the original hiPSC line) (Canals et al., 2015)
Multiline rationale Isogenic clones
Gene modification YES
Type of modification CRISPR/Cas9-mediated indels
Associated disease Sanfilippo B syndrome
Gene/locus NAGLU/17q21.2
Method of modification CRISPR/Cas9














Ethical approval lnstitutional Review Board (IRB00003099) of the
Bioethical Commission of the University of Barcelona
(October 20, 2016)
1. Resource utility
Sanfilippo B syndrome is caused by mutations in the N-acetyl-alpha-
glucosaminidase (NAGLU) gene. The NAGLU-mutated hiPSCs generated
here, UBi001-A-3 and UBi001-A-4 together with the isogenic control
cell line UBi001-A, can be useful for disease modeling as well as to
identify potential therapeutic approaches for Sanfilippo B syndrome.
2. Resource details
NAGLU is a gene coding for a protein involved in the degradation of
heparan sulfate (HS), a glycosaminoglycan present in the extracellular
matrix. Mutations in NAGLU lead to lysosomal accumulation of un-
degraded HS molecules, resulting in dysfunction of the endolysosomal
system and causing Sanfilippo B syndrome. Patients present early-onset
progressive and severe neurodegeneration for which there is no treat-
ment available yet.
We targeted exon 5 of the NAGLU gene in a previously reported
healthy hiPSC line (UBi001-A) (Canals et al., 2015) to generate mutated
hiPSC lines using a CRISPR/Cas9-mediated editing system (Fig. 1A). A
sgRNA targeting NAGLU exon 5 together with the ribonucleoprotein
Cas9 were used to disrupt the gene by non-homologous end joining
(NHEJ). After 48–72 h of transfecting UBi001-A cell line with Cas9-
sgRNA complex, sorted single cells were plated into laminin-coated 96-
well plates for single cell culture and expansion. To analyze colony
genotypes, genomic DNA was isolated and the regions flanking the
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targeted exon 5 were amplified by PCR, followed by Sanger sequencing,
which allowed us to find two homozygous mutated hiPSC clones
(Fig. 1B) that were further characterised.
The UBi001-A-3 presented a homozygous 9-bp deletion, which re-
sults in the loss of 3 amino acids (p.F288_I290del), from the 743-ami-
noacid NAGLU protein. UBi001-A-4 had a 1-bp insertion in
(caption on next page)
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homozygosis, causing a frameshift that changed the open reading frame
(p.F288Ifs*27) and lead to a shorter protein product of only 315 aa
(Fig. 1B and C, and Table 1). Both mutations caused a clear reduction in
NAGLU enzyme activity when compared to the parental cell line levels,
in hiPSCs and induced neurons (iNs) derived from the same hiPSC lines
(Fig. 1D). Interestingly hiPSCs lysosomal enzymes have low activity
levels, as we have previously reported for HGSNAT (Canals et al., 2015;
Benetó et al., 2019).
Both cell lines presented typical stem cell-like morphology (Fig. 1E)
normal karyotype (Fig. 1F), and were mycoplasma free (Fig. S1B).
Immunocytochemistry assays demonstrated the expression of plur-
ipotency markers OCT4 (aka POU5F1) and NANOG in our mutant
hiPSC lines (Fig. 1G), as well as their potential to differentiate into the
three germ layers (Fig. 1H). We also confirmed in a RT-qPCR that both
mutated hiPSC lines expressed high levels of pluripotency markers
NANOG and OCT4 and low levels of the neuronal marker TUJ1 (aka
TUBB3) when compared to induced neurons (iNs) (Fig. 1I). Short
tandem repeat (STR) analysis confirmed that both cell lines, UBi001-A-
3 and UBi001-A-4, had their origin from the hiPSC parental cell line
(UBi001-A) (loci listed on Fig. S1A). Finally, the top-five predicted off-
target sites of the sgRNA used were sequenced to confirm that no un-
desired editing was present in these newly established cell lines (Fig.
S1C).
3. Materials and methods
3.1. Cell culture
hiPSC were cultured as in (Benetó et al., 2019).
3.2. CRISPR/Cas9-mediated mutation
5 x 104 healthy hiPSC per well were plated in Biolaminin521-coated
24-well plates with 10 µM Y-27632 (#72302, STEMCELL Technologies)
in StemFlex medium with P/S for 24 h. The day after, cells were
transfected with a complex formed by the TrueCut Cas9 Protein v2
(#A36497, Invitrogen) and a pre-designed TrueGuide sgRNA Modified
(AssayID: CRISPR1108362_SGM, #A35511, Invitrogen) using
Lipofectamine Stem Transfection Reagent (#STEM00001, Invitrogen).
48–72 h after transfection, cells were individually replated after cell
sorting onto Biolamina521-coated 96-well plates in the presence of
10 µM Y-27632. Cells were allowed to expand before being analysed by
PCR and Sanger sequencing (Table 3).
Fig. 1. Characterization of NAGLU-mutated hiPSC lines UBi001-A-3 (NAGLU3) and UBi001-A-4 (NAGLU4). (A) Illustration showing CRISPR/Cas9 strategy for
the NAGLU gene, with the sgRNA targeting exon 5. (B) Sanger-sequencing and alignment of both mutated cell lines, showing deletions (in red) and insertions (in
green). (C) Scheme of the different resultant proteins, illustrating amino acids in frame (black), amino acid deletions (red) and those after the frameshift (gray). (D)
NAGLU activity levels in the different hiPSCs and iNs lines, expressed in nmol/h • mg protein (**** P value <0.0001, ** P value <0.01, unpaired t-test with Welch's
correction for 3 independent experiments with 2 technical replicates). (E) Representative bright-field images showing typical stem cell morphology. Scale
bar = 100 μm. (F) Results of the karyotype analysis for both cell lines. (G) Representative images of the immunofluorescence staining for pluripotency markers OCT4
(green) and NANOG (red), and DAPI (blue) for nuclei. Scale bar = 100 μm. (H) In vitro differentiation assay to the three germ layers: α-SMA (for mesoderm, green,
scale bar = 20 μm), AFP (for endoderm, red, scale bar = 50 μm) and TUJ1 (for ectoderm, red, scale bar = 20 μm). (I) Real-time quantitative PCR analysis showing
expression of pluripotent genes POU5F1 (OCT4) and NANOG, and neural marker TUBB3, normalized to GAPDH expression both in hiPSC lines (iPSCs) and induced
neurons (iNs). Results are represented as the fold change in gene expression of iNs compared to hiPSC. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease












Classification Test Result Data
Morphology Photography Normal Fig. 1 Panel E
Phenotype Qualitative analysis
(Immunocytochemistry)
Expression of pluripotency markers: OCT4 and NANOG Fig. 1 Panel G
Quantitative analysis (RT-qPCR) Relative expression of pluripotency markers: positive for
OCT4 and NANOG
Fig. 1 Panel I
Genotype Karyotype (G-banding) and resolution 46 XY, Resolution 550–650 Fig. 1 Panel F
Identity Microsatellite PCR (mPCR) OR STR analysis Not performed
16 loci tested, 100% matched Available with the authors
Mutation analysis (IF APPLICABLE) Sequencing Compound heterozygous mutation in both cases Fig. 1 Panel B
Off-target analysis Top 5 predicted off-target analysed and all sequence were
correct
Supplementary Figure 1 Panel
C
Microbiology and virology Mycoplasma Negative Supplementary Figure 1 Panel
B
Differentiation potential Embryoid body formation and
differentiation
Endoderm: a-feto protein (AFP), mesoderm: muscle actin
(a-SMA), and ectoderm: P-tubulin (TUJ1).
Fig. 1 Panel H
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C Not performed
Genotype additional info
(OPTIONAL)
Blood group genotyping Not performed
HLA tissue typing Not performed
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3.3. Karyotyping, STR analysis and mycoplasma detection
For the karyotype analysis, hiPSC were prepared using 2 ng/ml
colcemid (#15212-046, Invitrogen) during 45 min and harvested with
StemPro Accutase, then AMBAR (Anàlisis Mèdiques Barcelona) ana-
lysed 20 metaphases of each cell line. For STR analysis, AMBAR used
gDNA (DNeasy Blood & Tissue Kit #69504, Qiagen) to compare 16
different loci (listed on Fig. S1B) between each mutated cell line and the
parental hiPSC. For mycoplasma analysis, Mycoplasma Detection Kit
(#4542, Biotools) was used following the manufacturer's instructions.
3.4. NAGLU enzyme activity
Enzyme activity was measured as described in Marsh and
Fensom (1985).
3.5. Embryonic body (EB) formation and in vitro differentiation
EBs formation differentiation was performed as in
Canals et al. (2015) with minor modifications. hiPSC were maintained
in StemFlex medium with P/S, and thiazovivin was added from dis-
tribution of hiPSC in 96-well plates until EBs were put in suspension.
3.6. Immunofluorescence staining
Cells were fixed in 4% PFA for 15 min, blocked and permeabilised
with TBS containing 0.1% Triton-X 100 (#28817.295, VWR) and 5%
normal donkey serum (#S30-100 M, Merck Millipore) (TBS++) for 2 h
at room temperature. Primary antibodies (Table 3) were incubated
overnight at 4 °C. Secondary antibodies (Table 3) were incubated 2 h at
room temperature. Nuclei were stained with 0.5 μg/ml DAPI (#D1306,
Invitrogen). Both antibodies and DAPI were diluted in TBS++. Slides
were mounted with MOWIOL (#475904, Millipore). hiPSC images were
acquired with ZOE Fluorescence Cell Imager (Bio Rad), images from
EBs differentiated into ectoderm (TUJ1) and mesoderm (α-SMA) were
acquired using Zeiss confocal microscope LSM 880, and images from
EBs differentiated into endoderm (AFP) were acquired using Leica
confocal TCS-SP2 microscope. All images were analysed with the Fiji
software (Schindelin et al., 2012).
3.7. Direct neural differentiation and RT-qPCR analysis
Ngn2-induced neurons (iNs) were generated as described in
Zhang et al. (2013). Seven days after induction, RNA from iNs was
extracted using High Pure RNA Isolation Kit (#11828665001, Roche)
and 2 µg of total RNA were used to synthesize cDNA, using the High
Capacity cDNA Reverse Transcription kit (#4368814, Applied Biosys-
tems) and the RNase Inhibitor (#N8080119, Applied Biosystems) fol-
lowing manufacturer's instructions. Real-time qPCR was performed in a
LightCycler 480 II (Roche) system with the LightCycler 480 Probes
Master (#04887301001, Roche). GAPDH was used as normaliser.
TaqMan probes are listed in Table 3.
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Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-OCT4 1:100 Santa Cruz Biotechnology #sc- 5279, RRID: AB_628051
Rabbit anti-NANOG 1:100 Abcam #ab21624, RRID: AB_446437
Differentiation Markers Rabbit anti-AFP 1:100 DakoCytomation (now part of Agilent) #A0008, RRID: AB_2650473
Mouse anti-SMA 1:100 Sigma-Aldrich #A5228, RRID: AB_262054
Rabbit anti-TUJ1 1:500 Covance #MRB-435P, RRID: AB_663339
Secondary antibodies Donkey anti-mouse Cy2 1:200 Jackson Immunoresearch #715225-150, RRID: AB_2340826
Donkey anti-rabbit Cy3 1:200 Jackson Immunoresearch #711165-152, RRID: AB_2307443
Primers
Target Forward/Reverse primer (5′−3′)
Targeted mutation NAGLU Exon 5 GGCAAGAGAAACCAGGAGC/ GTGTGTTATGGCGAGGCATT
Potential off-target POT1: TTCAGATAAAGGGGAATATG CCGATTTTACAACTCATTGCC / CAAAT GTTGTCGCT CTTAGT C
POT2: TATATTCCCCATCATCTAGA GACAAGAGGTAGGTAGCAAG/ GAGAATGTGGGAGAAAGGAG
POT3: CAT ATT CT CCATT CTT GGGA TGCCTGTTCACTCTGATGGT / GGCTCAGAGTAGGTGGTGTT
POT4: CAT ATT CCCCAT CACT GTGG GGGT AAAT GAGGTGTCTATCGC / ATCTCAGCACTTTGGAAGGC
POT5: CAT ATT CT CCAT CGTCTGGG TGAGACTCCTACTTGAAGCCA / IIIIGTGCTGCTGTCCCATG
Probes for RT-qPCR
Target Assay ID (#4331182, TaqMan)
Pluripotency markers NANOG Hs02387400_g1
OCT4 Hs01654807_s1
Neural marker TUJ1 Hs00801390_s1
House Keeping GAPDH Hs99999905_m1
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